nateglinide

Also known as DJN608, AY-4166, SDZ-DJN-608, trans-N-{[4-(1-methylethyl)cyclohexyl]carbonyl}-D-phenylalanine, AY4166, A-4166, AY 4166, A 4166

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.

Research

622 papers

Nateglinide.2006
Nateglinide.2012
Nateglinide: A comprehensive profile.Profiles of drug substances, excipients, and related methodology · 2025
Nateglinide.Drugs · 2000
Nateglinide.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2001

via PubMed

Wikidata facts

Mass: 317.1991

Show 6 more facts

chemical formula: C₁₉H₂₇NO₃
World Health Organisation international non-proprietary name: nateglinide
isomeric SMILES: CC([C@H]1CC[C@@H](CC1)C(=O)N[C@@H](C(=O)O)CC2=CC=CC=C2)C
canonical SMILES: CC(C1CCC(CC1)C(=O)NC(C(=O)O)CC2=CC=CC=C2)C
defined daily dose: 0.36
Commons category: Nateglinide

Sources (9)

via Wikidata · CC0

~3 min read

Article

7 sections

Contents

Pharmacology
Contraindications
Comparisons with other drugs for type 2 diabetes
Dosage
See also
References
External links

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 462258838 | IUPAC_name = (2R)-2-({[trans-4-(1-methylethyl)cyclohexyl]carbonyl}amino)-3-phenylpropanoic acid | image = Nateglinide.svg | image_class = skin-invert-image